
A Phase I trial of zzso administered as a 120 h infusion once every 3 weeks was conducted in 20 patients with advanced zzso The initial dose was 5 zzso zzso zzso total zzso and patients received 10 zzso 25 zzso 30 zzso and 36 zzso zzso courses of zzso were administered and all patients were zzso for zzso Grade 4 zzso was the dose limiting toxicity observed in 50% of patients treated with 36 zzso zzso zzso was also observed at 30 and 36 zzso All toxicity resolved within three weeks of treatment and no cumulative toxicity was zzso No zzso or zzso was observed and no episodes of hypersensitivity reaction were zzso We conclude that 30 zzso is an appropriate dose for phase II testing of this zzso 

